Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

Novartis

Status and phase: Terminated; Phase 2

Conditions: Asthma

Treatments: Drug: QAV680; Drug: QAV680 Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01103037

CQAV680A2201E1

2009-017267-41 (EudraCT Number)

Details and patient eligibility

About

This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma

Enrollment: 8 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with moderate persistent asthma

Exclusion criteria

• Smokers
• Any significant disease or illness, other than asthma

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

8 participants in 2 patient groups, including a placebo group

QAV680

Experimental group

Treatment:

Drug: QAV680

QAV680 Placebo

Placebo Comparator group

Treatment:

Drug: QAV680 Placebo